From articles in Forbes to podcast featuring Steve Gorlin, see our latest news here

SRC-3: CoRegen’s revolutionary approach to cancer

Drug Target Review’s Taylor Mixides exclusively interviewed David Lonard, PhD, Chief Scientific Officer at CoRegen and Associate Professor at Baylor University, to uncover the mechanisms of SRC-3 and why it’s key to targeting cancer – and only cancer. See full interview below or at Drug Target Review

Read More